Business
REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024
Pivotal topline results from the CAMPSIITE® trial of RGX-121 for the treatment of MPS II to be presentedConference call Wednesday, February 7, 4:30 p.m.
About this update from Regenxbio Inc.
[{"type":"text","content":"Pivotal topline results from the CAMPSIITE® trial of RGX-121 for the treatment of MPS II to be presentedConference call Wednesday, February 7, 4:30 p.m. ETROCKVILLE, Md., Jan. 31, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations on its program for the treatment of mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, will be shared at the 20th Annual WORLDSymposium™ 2024, taking place in San Diego, CA February 3-9, 2024.\nThe presentations include the topline results from the pivotal phase of the Phase I/II/III CAMPSIITE® trial of RGX-121 for the treatment of MPS II.\nThe oral presentations will be presented as follows:\nAbstract Title: CAMPSIITE® Phase I/II/III: An interim clinical study update of RGX121, an investigational gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II)Presenter: Paul Harmatz, M.D., UCSF Benioff Children's HospitalDate/Time: Wednesday, February 7, 2024; 8:36 a.m. PT\nREGENXBIO will also present at the 3rd Annual Robert J. Gorlin Symposium on Tuesday, February 6, 2024 to discuss intracisternal administration of investigational AAV9 gene therapies to target the central nervous system in pediatric lysosomal disorders.\nThe poster presentations will be presented as follows:\nAbstract Title: Audiology assessment of participants in CAMPSIITE®, a phase I/II/III study of RGX-121 in neuronopathic MPS II (abstract 037)Presenter: Nidal Boulos, Ph.D., Director, Clinical Science, REGENXBIODate/Time: Thursday, February 8, 2024; 3 p.m. PT\nAbstract Title: Caregiver Perspectives on their MPS II Journey (abstract 422)Presenter: Vivian Fernandez, Executive Director, Patient Advocacy, REGENXBIODate/Time: Thursday, February 8, 2024; 3 p.m. PT\nConference CallREGENXBIO will host a conference call Wednesday, February 7 at 4:30 p.m. ET with Dr. Harmatz and Raymond Wang, M.D., Children's Hospital of Orange County to discuss the CAMPSIITE trial pivotal phase topline results and the expedited plan for filing a Biologics License Application using the accelerated approval pathway in 2024.\nListeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A copy of the slides being presented will be available via the Company's investor website. Those who plan on participating ...